Alterity Therapeutics Limited | PRAN


Peers Price Chg Day Year Date
CSL 209.25 -1.60 -0.76% -31.17% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Life Technologies 5.61 0.14 2.56% 198.40% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05

Alterity Therapeutics Limited traded at $1.91 this Tuesday April 9th, increasing $0.03 or 1.60 percent since the previous trading session. Looking back, over the last four weeks, Alterity Therapeutics Limited gained 11.70 percent. Over the last 12 months, its price fell by 32.27 percent. Looking ahead, we forecast Alterity Therapeutics Limited to be priced at 1.90 by the end of this quarter and at 1.87 in one year, according to Trading Economics global macro models projections and analysts expectations.

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.